Jim Woodgett, PhD
Jim Woodgett, Ph.D. emigrated to Canada from the UK to join the Ontario Cancer Institute in 1992 where his biomedical research laboratory focused on the signalling mechanisms that underscore malignant growth, degenerative diseases and diabetes. He was an International Scholar of the Howard Hughes Medical Institute for 10 years. In 1997 he was appointed Head of the Division of Experimental Therapeutics, held the Amgen Chair of Cancer Biology and became Full Professor in the Department of Medical Biophysics at the University of Toronto. Jim Woodgett has been an MRC Scientist and CIHR Senior Scientist and is known globally for his work on a class of proteins that regulate cellular processes, termed protein kinases. These molecules have become important drug targets for many diseases including cancer, schizophrenia, Alzheimers Disease and type-II diabetes. He was appointed as the fourth director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital from 2005-2020. In 20021 he was appointed President and Scientific Director of the Terry Fox Research Institute. He maintains his research group at Mount Sinai Hospital and has been internationally recognized for his discoveries of PKB/Akt and SAPK/JNKs. Jim is also the leading authority on the function of GSK-3. He has published over 320 scientific articles, and is an elected fellow of the Royal Society of Canada and Canadian Academy of Health Sciences. Why I’ve never been more optimistic about defeating the curse of cancer - realizing Terry Fox’s dream. Jim Woodgett will discuss how Canadian researchers, patients and clinicians have come together over the past 6 years to map the molecular details of 15,000 patients and how they plan to make access to the most effective therapies available to all Canadians, no matter where they live. From new discoveries to clinical trials, everything is changing.
Jim Woodgett, Ph.D. emigrated to Canada from the UK to join the Ontario Cancer Institute in 1992 where his biomedical research laboratory focused on the signalling mechanisms that underscore malignant growth, degenerative diseases and diabetes.
He was an International Scholar of the Howard Hughes Medical Institute for 10 years. In 1997 he was appointed Head of the Division of Experimental Therapeutics, held the Amgen Chair of Cancer Biology and became Full Professor in the Department of Medical Biophysics at the University of Toronto.
Jim Woodgett has been an MRC Scientist and CIHR Senior Scientist and is known globally for his work on a class of proteins that regulate cellular processes, termed protein kinases. These molecules have become important drug targets for many diseases including cancer, schizophrenia, Alzheimers Disease and type-II diabetes.
He was appointed as the fourth director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital from 2005-2020. In 20021 he was appointed President and Scientific Director of the Terry Fox Research Institute. He maintains his research group at Mount Sinai Hospital and has been internationally recognized for his discoveries of PKB/Akt and SAPK/JNKs. Jim is also the leading authority on the function of GSK-3. He has published over 320 scientific articles, and is an elected fellow of the Royal Society of Canada and Canadian Academy of Health Sciences.
Why I’ve never been more optimistic about defeating the curse of cancer - realizing Terry Fox’s dream.
Jim Woodgett will discuss how Canadian researchers, patients and clinicians have come together over the past 6 years to map the molecular details of 15,000 patients and how they plan to make access to the most effective therapies available to all Canadians, no matter where they live. From new discoveries to clinical trials, everything is changing.
This event is part of the Spring 2026 Speaker series.
Founding Members
Governance & Compliance - Bylaws
Speaker Events
7 Great Reasons to Join
.JPG)
